Lv1
86 积分 2023-09-26 加入
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
5小时前
已完结
The most frequent HLA alleles around the world: A fundamental synopsis
1个月前
已关闭
Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019
3个月前
已完结
Regulatory Forum Opinion Piece*
3个月前
已完结
Design of high specificity binders for peptide-MHC-I complexes
6个月前
已完结
Tracking the physical stability of fluorescent-labeled mAbs under physiologic in vitro conditions in human serum and PBS
6个月前
已完结
Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening
9个月前
已完结
Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method
9个月前
已完结
Challenges and solutions for therapeuticTCR‐based agents
9个月前
已完结
In vitro hemolysis: Guidance for the pharmaceutical scientist
10个月前
已完结
皖公网安备34019202002308
